A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy

  • Carey D
  • Baker D
  • Rogers G
 et al. 
  • 13

    Readers

    Mendeley users who have this article in their library.
  • 36

    Citations

    Citations of this article.

Abstract

BACKGROUND: Facial lipoatrophy can stigmatize and can reduce quality of life, self esteem, and antiretroviral adherence. Poly-L-lactic acid (PLA) injections seem safe and effective, but no randomized study has included objective endpoints. METHODS: HIV-positive adults with moderate/severe facial lipoatrophy were randomized to 4 open-label PLA treatments administered every 2 weeks from week 0 (immediate group, n = 51) or after week 24 (deferred group, n = 50). The primary endpoint was mean change in facial soft tissue volume (FSTV), as assessed by spiral computed tomography. Analyses were by intention to treat. RESULTS: At week 24, mean changes in FSTV were 0 cm3 in the intermediate group and -10 cm3 in the deferred group (between-group difference of 10 [95{%} confidence interval (CI): -7 to 28] cm3; P = 0.24). The immediate group had a greater mean change in soft tissue depth at the maxilla (2.2 mm [95{%} CI: 1.6 to 2.9]; P {

Author-supplied keywords

  • HIV
  • Lipoatrophy
  • Poly-L-lactic acid

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Dianne L. Carey

  • David Baker

  • Gary D. Rogers

  • Kathy Petoumenos

  • John Chuah

  • Nicole Easey

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free